AVH on NASDAQ, page-428

It is really sad how many here seem to want to treat these forums like a dedicated space for cult like worshippers who are only too eager to quickly shout down anyone raising any issue as a 'downramper', while anyone who throws out a high price target without any basis is left unquestioned.

It's sad, because there were a number of signs that sales growth was not growing anywhere near what they should be delivering, but no one wanted to discuss them.

Instead, there was such a big focus in here on what the NASDAQ listing would do for the share price, which is just stupid, because as I pointed out before - ASX listed biotech/medical devices companies are generally priced at higher multiples than those listed on the NASDAQ, which suggested that if wanted to use the logic that a NASDAQ listing would have an impact on the share price - it would be downward.

Turns out all the downrampers were right, and as more people realise there are challenges ahead for this stock, and with a lot of better risk-reward opportunities out there, when the full set of numbers come out, this may very well see the share price sink even further.